14 Jun, 2022. Tue Online PharmacyDostarlimab
It is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1) used in the treatment of mismatch repair deficient endometrial cancers and solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Dostarlimab was approved for medical use in the United States (US) and the European Union (EU) in April 2021. Dostarlimab works by binding to PD-1 to block interactions between PD-1 and PD-L1 or PD-L2. This releases the PD-1 pathway-mediated inhibition of the anti-tumor immune response to kill cancer cells.